These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29846090)

  • 1. Precise predictive and therapeutic strategy for breast cancer.
    Kyrochristos ID; Peristeri DV; Ziogas DE; Lykoudis EG; Roukos DH
    Future Oncol; 2018 Aug; 14(18):1777-1780. PubMed ID: 29846090
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: Targeted therapy for HER-2: personalized medicine for her, too.
    Melichar B; Plebani M
    Clin Chem Lab Med; 2012 Jan; 50(1):1-4. PubMed ID: 22505535
    [No Abstract]   [Full Text] [Related]  

  • 3. The Evolving Landscape of HER2 Targeting in Breast Cancer.
    Moasser MM; Krop IE
    JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib Graduates to I-SPY 3.
    Cancer Discov; 2014 Jun; 4(6):624. PubMed ID: 24891343
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic therapy for HER2-positive early-stage breast cancer.
    Mathew A; Romond EH
    Curr Probl Cancer; 2016; 40(2-4):106-116. PubMed ID: 27816189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 7. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New omics information for clinical trial utility in the primary setting.
    Damia G; Broggini M; Marsoni S; Venturini S; Generali D
    J Natl Cancer Inst Monogr; 2011; 2011(43):128-33. PubMed ID: 22043059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Med Res Rev; 2019 May; 39(3):1205-1227. PubMed ID: 30417574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
    Iyer PM; Karthikeyan S; Sanjay Kumar P; Krishnan Namboori PK
    Funct Integr Genomics; 2017 Jul; 17(4):375-385. PubMed ID: 28470340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where to with HER2?
    Sledge GW
    Clin Breast Cancer; 2010 Feb; 10(1):18. PubMed ID: 20133253
    [No Abstract]   [Full Text] [Related]  

  • 12. Improving treatment of HER2-positive cancers: opportunities and challenges.
    Stern HM
    Sci Transl Med; 2012 Mar; 4(127):127rv2. PubMed ID: 22461643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
    Lumachi F; Chiara GB; Foltran L; Basso SM
    Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 17. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Expression Assays in Early-Stage Breast Cancer.
    Sparano JA
    Oncology (Williston Park); 2018 Oct; 32(10):510-2. PubMed ID: 30334241
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging Therapeutic Strategies in Breast Cancer.
    Cox K; Alford B; Soliman H
    South Med J; 2017 Oct; 110(10):632-637. PubMed ID: 28973703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neratinib after trastuzumab in patients with HER2-positive breast cancer.
    Hasegawa T; Uno H; Wei LJ
    Lancet Oncol; 2016 May; 17(5):e176. PubMed ID: 27301038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.